title: The Value of Addressing Patient Preferences.
abstract: Recent scientific progress is, in some cases, leading to transformative new medicines for diseases that previously had marginal or even no treatment options. This offers great promise for people affected by these diseases, but it has also placed stress on the health care system in terms of the growing cost associated with some new interventions. Effort has been taken to create tools to help patients and health care providers assess the value of new medical innovations. These tools may also provide the basis for assessing the price associated with new medical products. Given the growing expenditures in health care, value frameworks present an opportunity to evaluate new therapeutic options in the context of other treatments and potentially lead to a more economically sustainable health care system. In summary, the contribution to meaningful improvements in health outcomes is the primary focus of any assessment of the value of a new intervention. A component of such evaluations, however, should factor in timely access to new products that address an unmet medical need, as well as the magnitude of that beneficial impact. To achieve these goals, value assessment tools should allow for flexibility in clinical end points and trial designs, incorporate patient preferences, and continually evolve as new evidence, practice patterns, and medical progress advance.
authors.affiliation: Friends of Cancer Research, Washington, DC, USA. Electronic address: jallen@focr.org.
authors.forename: Jeff D
authors.initials: JD
authors.lastname: Allen
authors.affiliation: Friends of Cancer Research, Washington, DC, USA.
authors.forename: Mark D
authors.initials: MD
authors.lastname: Stewart
authors.affiliation: Friends of Cancer Research, Washington, DC, USA.
authors.forename: Samantha A
authors.initials: SA
authors.lastname: Roberts
authors.affiliation: Friends of Cancer Research, Washington, DC, USA.
authors.forename: Ellen V
authors.initials: EV
authors.lastname: Sigal
mesh_terms: D000970:Antineoplastic Agents; D055808:Drug Discovery; D006801:Humans; D009369:Neoplasms / Q000188:drug therapy; D057240:Patient Preference; D062505:Value-Based Purchasing
chemical_list: D000970:Antineoplastic Agents
keywords: assessment; breakthrough therapies; cancer; value framework